wint stock: Windtree Therapeutics, Inc.
Windtree Therapeutics, Inc. (WINT)
Lead summary
Windtree Therapeutics, Inc. (ticker: WINT) is a clinical‑stage biopharmaceutical company focused on acute cardiovascular and pulmonary therapies. As a publicly traded microcap, wint stock has been the subject of frequent news, clinical updates and corporate reorganization announcements in recent years. This entry summarizes Windtree’s business, pipeline, governance and the trading profile of wint stock so readers know where to find authoritative disclosures and what key risks to consider.
Company overview
Windtree (WINT) was formed to develop therapeutics for acute heart and lung conditions, including surfactant replacement therapies and cardiac agents. The company’s headquarters, founding year and mission are documented on the Windtree investor relations pages; investors tracking wint stock commonly reference company press releases and SEC/OTC filings for updates.
History and corporate timeline
Major milestones include product acquisitions and licensing of pulmonary assets, clinical trial initiations and corporate restructurings. Public filings and press reports have recorded changes in leadership, financing rounds and occasional proposals affecting the capital structure—all items that can materially affect wint stock.
Products, pipeline and research programs
Windtree’s programs have included surfactant‑based therapies for neonatal respiratory distress and cardiac candidates aimed at acute heart failure. Program names and clinical stages are described in company disclosures; progress or setbacks reported in press releases often move wint stock prices.
Corporate strategy, partnerships and licensing
Windtree has entered licensing and commercialization agreements for pulmonary assets and has reviewed strategic options for commercializing or out‑licensing programs. Any announced strategy or proposal is presented in company filings and has been noted in market commentary related to wint stock.
Financials and capital structure
Wint stock trades as a small/microcap issue with a history of limited revenue and periodic financing events. The company has reported equity raises, preferred‑stock transactions and share authorizations in regulatory filings—items that can dilute or change the outstanding share count and affect holders of wint stock.
Stock listing and trading information
WINT is publicly quoted on market data services and OTC/Nasdaq reporting venues. Market pages (e.g., Yahoo Finance, Nasdaq) provide up‑to‑date quotes, 52‑week ranges and volume statistics for wint stock. Traders should confirm quoted venue and ticker when viewing price data.
Market performance and historical price action
Wint stock has shown the volatility typical of clinical‑stage microcaps, including wide intraday swings and notable 52‑week extremes reported by market data providers. This reflects low float, event‑driven news and limited liquidity.
Trading profile and liquidity
Average volume for wint stock tends to be low compared with larger equities, producing wider bid–ask spreads and elevated trading risk. Social channels and stock message boards sometimes amplify short‑term moves in wint stock.
Major corporate events and controversies
Material events—clinical readouts, licensing deals and shareholder‑vote items—are disclosed through Windtree press releases and official filings. As of Jan 26, 2026, according to Windtree investor relations and Yahoo Finance, these disclosures remain the primary sources for factual updates that influence wint stock.
Governance and management
Executive and board biographies, insider holdings and governance notices are available in company filings. Changes in leadership or significant insider transactions have featured in reports affecting wint stock sentiment.
Regulatory, clinical and legal matters
Windtree’s programs are subject to regulatory review (e.g., FDA interactions) and clinical trial oversight. Any material legal proceedings or regulatory actions are disclosed in filings and can materially affect wint stock.
Shareholders and ownership
Institutional ownership of wint stock has historically been limited; retail investors and insiders often represent a meaningful portion of the reported float. Major holders and ownership changes are disclosed in periodic filings.
Investor relations and disclosures
Investors should consult Windtree’s investor relations page, press releases and official filings for primary-document disclosure. Market pages (Yahoo Finance, Nasdaq, CNBC) and message feeds (StockTwits, Public) provide secondary quotes and sentiment but should not replace company filings when researching wint stock.
Risk factors
Key risks include clinical and regulatory uncertainty, limited revenue, dilution from financings, low liquidity and the volatility common to penny/microcap equities. These risk factors are described in company risk disclosures and are relevant to any analysis of wint stock.
See also
- Clinical‑stage biopharmaceutical company
- Penny stock / microcap risk
- Drug development and FDA regulatory pathway
References
- Windtree Therapeutics — Investor Relations and official press releases (company filings)
- Yahoo Finance — WINT quote and market statistics
- Nasdaq — WINT company summary and listing information
- CNBC / MSN — market quote summaries and related news items
- StockTwits, Public.com, Robinhood and Moomoo — public trading feeds and sentiment
- Aggregated press coverage (e.g., StockTitan) and market news summaries
External links
- Windtree investor relations (official company disclosures)
- Market quote services and major data providers listed above (use market pages to follow wint stock)
Further exploration
To follow wint stock price action, review Windtree’s filings and visit market data pages regularly. If you trade or custody equities, consider using Bitget for supported trading and Bitget Wallet for custody solutions. This article is factual and informational only; it does not constitute investment advice.
